Thailand’s health authorities on Thursday encouraged people to make
hand sanitizers and masks at home to guard against the spread of the new
coronavirus.
Thailand, which has reported a total of 25 cases, put surgical masks
and sanitizers under its list of controlled goods earlier this week, as
the spread of the flu-like virus led to shortages in stores.
Due to lack of supply, health authorities demonstrated how to make sanitising liquids during a televised news conference.
“If you can’t find hand sanitizers in stores, make it yourself. Mix
clean water with alcohol and carry it wherever you go,” said Public
Health Minister Anutin Charnvirakul at the conference.
“We have to protect ourselves against the virus. Eat hot food, use serving spoons, wear masks, wash your hands.”
On Thursday, Thailand started enforcing price control measures on
surgical masks and hand sanitizers, amid scarce supplies in drug stores.
As a result, anyone selling overpriced masks and sanitizers faces
punishment of up to seven years in jail or up to 140,000 baht
($4,507.41) in fines.
People are allowed to buy up to 10 masks with each purchase, and
anyone exporting more than 500 masks per shipment must also obtain
permission from trade authorities first.
Early on Thursday, Thais lined up outside a government pharmacy to stock up before sales started in the afternoon.
Many said they wanted to buy as much as they could due to fears of the virus outbreak, but could only buy 10.
“This isn’t really enough, but it’s good to have just in case,” said Chalida Potpanitpong, 65.
To ease the shortages, the Thai government started handing out 45,000
surgical masks for free from Thursday to Saturday at different “risky”
locations, mostly tourist areas, in Bangkok.
It will also start selling millions of masks from Saturday onwards through government-sponsored stores across the country.
The 25 cases of the new coronavirus reported in Thailand include 16
Chinese and nine Thais. Nine have recovered enough to go home, while the
rest remain in the hospital.
https://www.reuters.com/article/us-china-health-thailand/thailand-encourages-homemade-sanitizers-masks-amid-scarce-supplies-idUSKBN2001NQ
Thursday, February 6, 2020
Qiagen takeover likely, just further away – Evercore
In a note, Evercore ISI’s Luke Sergott says QIAGEN N.V. (NYSE:QGEN) is still an attractive acquisition target for science tool consolidators, but it will take longer than expected.
He published his report after a roadshow with
management. The company is rebooting its message with a focus on
execution and away from M&A.
https://seekingalpha.com/news/3539222-qiagen-takeover-likely-just-away-evercore
Protalix advancing study plan of PRX-102 in pediatric Fabry patients
Protalix BioTherapeutics (PLX +2%) and development partner Chiesi Farmaceutici S.p.A. announce that the FDA has signed off on the initial study plan for pegunigalsidase alpha (PRX-102) in pediatric patients with Fabry disease, an inherited disorder caused by the buildup of a certain type of fat in cells due to mutations in an essential enzyme.
The companies intend to request accelerated approval in the U.S. when they file a marketing application in April.
PRX-102 is chemically modified version of a recombinant therapeutic enzyme called alpha-galactosidase A.
https://seekingalpha.com/news/3539276-protalix-advancing-study-plan-of-prxminus-102-in-pediatric-fabry-patientsCortexyme up 25% on bullish private stock placement
Thinly traded Cortexyme (CRTX +24.7%) is up in early trade, albeit on below-average volume of only 50K shares, on the heels of its $125M private placement of stock to a group of institutional investors and an entity affiliated with a board member.
The company will issue 2.5M common shares at $50/share, almost a 10% premium to yesterday’s close of $45.64.
Closing date is February 10.
https://seekingalpha.com/news/3539267-cortexyme-up-25-on-bullish-private-stock-placementCigna EPS beats by $0.11, beats on revenue
Revenue of $36.54B (+165.7% Y/Y) beats by $1.34B.
https://seekingalpha.com/news/3539017-cigna-eps-beats-0_11-beats-on-revenueRegeneron Pharmaceuticals EPS beats by $0.59, beats on revenue
Regeneron Pharmaceuticals (NASDAQ:REGN): Q4 Non-GAAP EPS of $7.50 beats by $0.59; GAAP EPS of $6.93 beats by $0.71.
Revenue of $2.17B (+12.4% Y/Y) beats by $70M.
https://seekingalpha.com/news/3539037-regeneron-pharmaceuticals-eps-beats-0_59-beats-on-revenueTonix Pharmaceuticals down 60% premarket on failed Tonmya study
Tonix Pharmaceuticals (NASDAQ:TNXP) has decided to stop enrollment in a Phase 3 clinical trial, RECOVERY,
evaluatinng Tonmya (cyclobenzaprine HCl sublingual tablets) 5.6 mg
(TNX-102 SL) for the treatment of posttraumatic stress disorder (PTSD).
The company took action after a prespecified
interim analysis by the Independent Data Monitoring Committee showed
that the study is unlikely to achieve the primary endpoint.
It plans to continue studying the current
participants (50% enrolled) until completion, then proceed to a full
analysis of the unblinded data to determine next steps. Topline results
should be available next quarter.
Tonix will reallocate resources from the PTSD program to the Phase 3 fibromyalgia study of TNX-102 SL 5.6 mg. Interim data are expected in Q3.
Shares down 60% premarket on light volume.
https://seekingalpha.com/news/3539048-tonix-pharmaceuticals-down-60-premarket-on-failed-tonmya-study
Subscribe to:
Comments (Atom)